EQL Pharma (EQL) CMD 2025 summary

Strategic ambitions and financial targets

• New five-year plan targets 30% average annual sales growth (CAGR) to surpass SEK 1 billion in revenue by 2028/2029, focusing on organic growth and selective M&A as a supplement.

• EBITDA margin target is above 25% by the end of the period, with stabilization expected towards FY 28/29; margin may dip slightly mid-period due to launches.

• Net leverage ratio targeted below 2.5x, with a temporary ceiling of 4.0x for strategic investments or acquisitions.

• Revenue growth is prioritized over margin expansion to maximize long-term shareholder value.

• Acquisitions, if any, will be funded primarily through existing cash and potential new debt.

Business model and operational focus

• Operates an asset-light model, outsourcing manufacturing and development while focusing in-house on product identification, regulatory, and project management.

• Maintains a ~70% historical success rate in product launches, with a strategy to fail fast and minimize sunk costs.

• Capital allocation emphasizes rapid CapEx turnaround, with most projects achieving payback within two years and an average ROCE of 20%.

• OpEx as a percentage of sales has been reduced from 35% to 21%, with further efficiency gains targeted.

• Sustainability is integral, aiming to deliver affordable, accessible healthcare and reduce costs for patients and society.

Product and market development

• Portfolio includes 40 marketed products and 40 in the pipeline, with launches planned across pharmacy, hospital, branded, and specialty generics segments.

• Branded products Mellozzan (for pediatric ADHD-related insomnia) and Memprex (for recurrent urinary tract infections) are expanding in Europe via B2B partnerships, showing strong growth (Mellozzan 59% CAGR, Memprex 185% CAGR).

• Specialty generics target non-interchangeable products with higher margins (60–80%) and higher revenue per product (SEK 30–50m), supported by new hires in medical and commercial roles.

• Hospital segment growth is on track, with successful tender participation and a robust pipeline.

• Focuses on products with minimal generic competition post-patent expiry, enabling higher price retention and superior margin profiles.